ribosomal protein L9Genealiases: L9 · NPC-A-16 · uL6
Q-omics provides the consensus-scored RPL9 profile across patient tissues and cancer cell-line models. RPL9 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RPL9 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, RPL9 protein abundance shows 28,105 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, KIRC, and GBM as cancer lineages where RPL9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL9 survival associations across molecular data types. RPL9 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (1) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL9 RNA expression–survival associations across cancer types. High RPL9 expression shows unfavorable associations in ACC, HNSC and LIHC, but favorable associations in BRCA, BLCA and LGG. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RPL9 RNA expression.
This table summarizes RPL9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for RPL9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL9 shows lower tumor expression in BRCA, BLCA and UCEC and higher tumor expression in KIRC, LIHC and CHOL. The KIRC box plot shows higher RPL9 RNA expression in tumor versus normal tissue (log2 FC = +0.859, t-test p < 0.001).
This table shows molecular features associated with RPL9 in patient tissues and cancer cell lines. In patient samples, RPL9 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, RPL9 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and CNS.
